You are here : Home / All Sectors / Healthcare / Pharmaceuticals & Drugs / BIOCON

BIOCON
Intrinsic Value | Fundamental Analysis

Returns | 1W : -1.8% , 1M : 4.3%,1Y : 20.1%
BOM : 532523     NSE : BIOCON    
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive]
Debt : Average
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Mild Upward
Pledged Shares : None or < 25%
Apr 16,2021
Price(EOD): Rs. 412.80
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
MarketCap: Rs. 49,536.00 Cr
Stock Market Investing Simplified- The best Video Course by Smart-Investing.in

Check out Industry Peers

Peers & Returns1W1M1Y
BIOCON -1.8% 4.3% 20.1%
SUN PHARMACEUTICAL INDUSTRIES 1.4% 6.7% 41%
DR REDDYS LABORATORIES 2.8% 12.7% 27.3%
DIVIS LABORATORIES 1.9% 12.1% 58.1%
CIPLA 6.4% 16.6% 54.3%
AUROBINDO PHARMA 1% 14.2% 77.7%
LUPIN -2.2% -0.5% 29.5%
TORRENT PHARMACEUTICALS 1.8% 7.7% 11.6%
CADILA HEALTHCARE 2.4% 19.8% 48.7%

FUNDAMENTAL ANALYSIS OF BIOCON

 
Fundamentals Score
[Last Annual Data : Mar2020 | TTM
Trailing Twelve Months (TTM) is calculated using last 4 quarterly data and is a good substitute to track Annual results.
Learn More
]
Show Me the Stocks with Fundamentals better than BIOCON Premium


VALUATION OF BIOCON

 
Valuation Score
RatioValue
P/E
P/B
P/S
66.15
P/E Calculated based on EPS of 6.24
[ Mar2020 - Consolidated Results ]

7.51
P/B Calculated based on Book Value of 54.97
[ Mar2020 - Consolidated Results ]

7.34
P/S Calculated based on Revenues of 6745.2 Cr
[ TTM - Consolidated Results ]

Show Me the Stocks with Valuation better than BIOCON Premium


FAIR VALUE OF BIOCON

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
237%
153%
117%

SHARE PRICE MOMENTUM OF BIOCON

DEBT

Year Debt/Equity ratio
Standalone Consolidated
2020
2019
2018
Avg_3yrs
0
0.01
0.02
0.01
0.4
0.4
0.44
0.41
[Last Annual Data : Mar2020]

PLEDGED SHARES

Pledged Shares
0 %
As on : Sep2020

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad

QTRLY RESULTS

Consolidated 1 Qtr Growth 4 Qtr Growth
Revenue
Op Profit
EBIDT
Net Income
6.09%
5.04%
6.11%
-6.49%
7.82%
-10.96%
-25.76%
-19.74%
QtrlyTrend
0
Latest Qtr: Dec2020

BIOCON related INDICES

BSE Indices1W1M1Y
S&P BSE HEALTHCARE 1.2% 9.2% 53%
S&P BSE 100 LARGECAP TMC -1.5% -1.8% 62.2%
S&P BSE CARBONEX -1.6% -2.1% 64.8%
S&P BSE 100 -1.6% -2% 62.8%
S&P BSE 200 -1.7% -1.6% 65.2%
S&P BSE 250 LARGEMIDCAP -1.7% -1.6% 65.5%
S&P BSE LARGE MIDCAP -1.7% -1.9% 63.9%
S&P BSE 100 ESG INDEX -1.8% -2.5% 72.2%
S&P BSE 500 -1.8% -1.7% 67.2%
S&P BSE ALLCAP -1.9% -1.7% 68.2%
S&P BSE SENSEX NEXT 50 -2.7% -2.1% 59.7%
S&P BSE MIDSMALLCAP -2.8% -0.8% 87.9%
S&P BSE MID CAP -2.9% -1.3% 74.5%
S&P BSE MIDCAP SELECT INDEX -3.1% -2% 67.6%
NSE Indices1W1M1Y
NIFTY PHARMA 1.8% 10.1% 43.7%
NIFTY ALPHA LOW-VOLATILTY 30 -1.2% 4.5% 41.5%
NIFTY 100 -1.5% -1.8% 61.3%
NIFTY 100 EQUAL WEIGHT -1.6% -0.2% 64.5%
NIFTY 200 -1.7% -1.7% 64.1%
NIFTY 500 -1.8% -1.7% 66.6%
NIFTY NEXT 50 -2% 0.1% 48.7%
NIFTY LARGE MIDCAP 250 -2.2% -1.4% 73.1%

FAQ [Frequently Asked Questions]


Is BIOCON good for long term investment?

As on 16-Apr-2021, the Fundamentals of BIOCON are Strong and hence it's good for long term investment! See Financial Performance of BIOCON . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is BIOCON UnderValued or OverValued?

As on 16-Apr-2021, BIOCON is Over Valued and hence NOT a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of BIOCON ?

As on 16-Apr-2021, the Intrinsic Value of BIOCON is Rs. 163.26 determined based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 122.62
Fair Value [Median EV / Sales Model] : Rs. 163.26
Fair Value [Median Price / Sales Model] : Rs. 189.99
Median Fair Value of BIOCON : Rs. 163.26

Is BIOCON trading at a Premium or Discount?

As on 16-Apr-2021, BIOCON is trading at a Premium of 153% based on the Median Intrinsic Value!

Is it right time to buy BIOCON shares?

As on 16-Apr-2021, BIOCON is Over Valued and hence NOT a good buying opportunity according to Share Valuation at this time!

What is the Financial Performance of Industry Peers of BIOCON?

Check out Financials of Industry Peers using below links:
Financials of SUN PHARMACEUTICAL INDUSTRIES LTD
Financials of DR REDDYS LABORATORIES LTD
Financials of DIVIS LABORATORIES LTD
Financials of CIPLA LTD
Financials of AUROBINDO PHARMA LTD
Financials of LUPIN LTD
Financials of TORRENT PHARMACEUTICALS LTD
Financials of CADILA HEALTHCARE LTD
Financials of ABBOTT INDIA LTD
Financials of ALKEM LABORATORIES LTD

What are the Frequent Comparisons with BIOCON?

BIOCON LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs DR REDDYS LABORATORIES LTD
BIOCON LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD
BIOCON LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD
BIOCON LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs AUROBINDO PHARMA LTD
BIOCON LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs LUPIN LTD
BIOCON LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs TORRENT PHARMACEUTICALS LTD
BIOCON LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs CADILA HEALTHCARE LTD
BIOCON LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs ABBOTT INDIA LTD
BIOCON LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs ALKEM LABORATORIES LTD

Open Demat Account & Start Investing
    Affiliate Links

Disclosure

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].


All Stocks : A - Z

ALL   A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z